Introduction
N on-invasive imaging of molecular and biological processes in living subjects with positron emission tomography (PET) provides exciting opportunities to monitor metabolism and detect diseases in humans and in small animal models [1] . The first oncological application using 2-deoxy-2-[
18 F]fluoro-glucose ([ 18 F]FDG) for PET imaging of tumors was almost 25 years ago [2] . Since then, [ 18 F]FDG has become indispensable for the detection and grading of tumors and is also increasingly used for the monitoring of tumor response to therapy [3] [4] [5] . Radiolabelled thymidine, amino acid or choline derivatives such as 3′-deoxy-3′-[ 18 [6] , protein synthesis [7] or membrane assembly [8] .
Thymidine is a component consumed by rapidly growing cells via a salvage pathway for incorporation into DNA [9] . After using different nucleoside transporters, thymidine is directly phosphorylated by thymidine kinase-1 (TK-1), which is exclusively expressed in S-phase and further metabolized into thymidine triphosphate, acting as a substrate for DNA polymerase [10] [18] . A successful labeling method and first data in vitro as well as distribution in a patient were demonstrated by Wester et al. [19] . Results from larger groups of patients with [ [20, 21] , and intensive preclinical research with a more mechanistic focus was done on brain tumor models such as C6 rat glioma [22, 23] . It has also been shown that [ 18 
F]
FET selectively accumulates in tumors and not in inflammatory tissues [24] .
Choline and the fluorinated analogue [ 18 F]FCH are similarly transported into mammalian cells followed by phosphorylation, interacting with choline kinase, which is up-regulated in tumor cells. Choline is then metabolized to phosphatidylcholine, an essential cellular compound needed to assemble membranes [8] . Initial work, using [ as PET tracers to demonstrate the diagnostic potential of these compounds, i.e., diagnosing prostate tumors as well as lung and brain tumors, has been done by Degrado et al. [25, 26] and Hara et al. [27] [28] [29] [30] .
The purpose of this study was to evaluate potential PET tracer candidates besides [ 18 F]FDG for determining the optimal biomarker for each of various drug development candidates with different mechanisms of action. This was prompted by our observations that human tumor xenografts in athymic nude mice have a low and heterogeneous [ 18 F]FDG uptake per se [31] , which may limit the sensitivity of this approach in xenografts. In this report, the standardized uptake values (SUV) of [ 18 [7] .
Materials and Methods

Radiopharmaceuticals
Animal Handling
All experiments were carried out according to procedures covered by permit numbers (BS 1974/75) and approved by the Kantonales Veterinäramt Zurich and strictly adhered to the Federal animal protection law and the "Eidgenössische Tierschutzverordnung".
Female Brown-Norway (BN) rats, C3H/He and C57BL/6 mice were obtained from Charles River (France) and female Harlan Hsd: Npa nu/nu (nude) athymic mice were obtained from the Novartis breeding stock. Rats weighed between 135 and 180 g, whereas mice weighed 20-30 g prior to experiments. Depending on the growth rate of the tumor, animals were shipped to the imaging facility site 2-4 weeks after preparation, using appropriate transfer conditions. All animals were randomized based upon body weight and tumor volume measured beforehand by calipers. Animals were identified by tail and back labels or shaving and kept in groups of six to ten mice or three to five rats, respectively, under normal conditions with access to food and water ad libitum. Animals were killed by CO 2 inhalation (mice) or decapitation (rats).
Tumor Models
Mouse B16/BL6 metastatic melanoma were created as described [37] . Cells were cultured in supplemented minimum essential medium (2 mmol/L glutamine, 5% fetal calf serum (FCS), 1% sodium pyruvate, 1% nonessential amino acids, and 2% vitamins) and kept at confluence for 4-5 days (with a medium change every 48 h) before resuspension in Hank's balanced salt solution (+10% FCS). Using a Hamilton syringe, 5×10 4 cells were injected intradermally (i.d.) in a volume of 1 μL into the dorsal pinna of both ears of anesthetized C57BL/6 mice. After 1 week, the primary tumor was visible as a black dot in the middle of the ear, and after 10 days, the cervical lymph node metastases were detectable by palpitation. Mice were used for PET studies ca. 14 days after cell inoculation.
Murine RIF-1 fibrosarcoma cells were obtained as a gift from Ms Loreta Rodrigues (St George's Hospital Medical School, London, UK). Cells were cultured in RPMI medium supplemented with 10% FCS and 5 × 10 6 cells per mouse were injected subcutaneously (50 μL phosphate-buffered saline (PBS)) in the upper thigh of anesthetized female C3H/He mice. After 10-14 days, tumors were of sufficient size for PET studies.
BN472 rat mammary carcinoma tumors were created by transplantation of tumor fragments as described [38] . Briefly, frozen tissue or fresh tumor samples from earlier in-house studies were washed sterilely in saline containing 100 μg/mL gentamicin and then placed in a Petri dish containing Ham's F-12 medium with 100 μg/mL gentamicin and 10% FCS. The tumor tissue was divided into small pieces (3×3×3 mm), and one piece was inserted into a hole made by a 22-gauge sterile needle in the lowest mammary fat pad of anesthetized rats after wiping the skin with 70% alcohol. The hole was closed with two metal wound clips which were then removed after 3-4 days.
The human NSCLC cell line NCI-H-460 was obtained from the American Type Culture Collection and a stable luciferized version created in Novartis by retroviral infection. Using athymic nude mice, two different brain tumor models were evaluated as follows.
(1) H-460-Luc cells (5×10 4 in 10 μL PBS) were injected intracranially (i.c.) in the cortex. (2) Orthotopic lung model with spontaneous metastases to the lymph-nodes as well as brain: H-460-Luc cells (10 5 in 100 μL of Ca and Mg-free PBS) were injected into the pleural cavity. This number of cells permitted growth over a reasonable time without impacting too rapidly on mouse health, and lymph-node metastases (neck and legs) including some micro brain metastases appeared ca. 2 weeks later. Prior to PET experiments, growth was monitored non-invasively using the IVISTM-imaging system (Caliper, USA), and quantification of light emission was made with the Living ImageTMv2.20 software package by injecting the mice i.p. with 150 mg/kg of DLuciferinin in PBS (10 ml/kg) 15-20 min prior to imaging. Shipment to the PET imaging facility was done when the bioluminescent (BioL) signal was 910 2+ -free) in the anesthetized animal. In general, tumors grown at the skin were allowed to reach sizes of ≥200 mm 3 prior to PET imaging. However, due to different growth rates of the tumor models and the availability of scanner time, sometimes smaller tumors were used of 50-100 mm 3 and occasionally 10-50 mm 3 particularly for the i.c. tumors (H-460-Luc). However, in all cases, the PET system used (see below) was able to visualize these tumors with the appropriate tracer.
Drug Preparation and Treatment
Patupilone was obtained from Chemical Development, Novartis (Basel, Switzerland), and the powder was stored at −20°C. It was freshly prepared on each treatment day by dissolving in polyethylene glycol-300 (PEG-300) and then diluting with physiological saline (0.9% (w/v) NaCl) to obtain a mixture of 30% (v/v) PEG-300 and 70% (v/v) physiological saline for i.v. administration in the tail vein. The injection volume was 5 mL/kg for mice and 2 mL/kg for rats. Treatment with vehicle (PEG-300/saline) or patupilone was once weekly.
Several different experiments were performed with patupilone, where mice were treated i.v. with either patupilone (1-5 mg/kg) or the patupilone-vehicle (vehicle). In the two BioL experiments using human H-460-Luc cells in athymic mice ( Fig. 1 ), animals were divided into two groups (n=10 per group) and were treated once with vehicle or patupilone (4 mg/kg). In the dose-response experiment using murine RIF-1 tumors, mice were divided into four groups (n=8 per group) and treated once with vehicle or patupilone at 1, 3, or 5 mg/kg (Fig. 7) . For the longitudinal [
18 F] FLT experiment with extensive IHC (Figs. 8 and 9), mice were divided into two groups (n=20 per group) and treated with vehicle or patupilone (5 mg/kg). The same mice were studied by PET at baseline (day 0) as at 24 h when the mice were killed and the tumors ablated for IHC. The remaining 30 mice (five mice for each treatment group) were studied by PET prior to IHC at the subsequent three different time points posttreatment. This experimental protocol permitted correlation of IHC with [ 
Animal Monitoring
During the experiments, body weight (BW in grams) and tumor volume (TVol in cubic millimeter) were measured three times per week. Tumor dimensions were measured using a caliper, and TVol was calculated by the following equation: TVol=(pi/6)×x×y×z, where x, y, and z represent the three orthogonal axes of the tumor. Efficacy was assessed as the T/C from the change (subtraction) in TVol from day 0 (patupilone treatment) to the endpoint (at 1 week posttreatment initiation), T/C TVol =ΔTVol (treated) /ΔTVol (control) . In a similar manner, the effect of the drug on BW was also quantified, i.e., the fractional change in BW, ΔF-BW (BW after /BW before ), for both vehicle-control and drug-treated groups was determined and applied as follows: T/C BW =ΔF-BW (treated) /ΔF-BW (control) .
Small Animal PET Study, Image Acquisition, and Reconstruction
All PET experiments were performed at the Animal Imaging Center of ETH Zurich at the Center for Radiopharmaceutical Science using the Raw data files were acquired in list-mode and reconstructed in single time frame using the OPL-EM algorithm (i.e., voxel size of 0.125 mm 3 and matrix size of 120×120×100 for mouse double scanning and 240× 240×200 for rats) [40] . Reconstruction did not include scatter, random, and attenuation correction. A simultaneous Na-22 point source measurement was used as internal standard to correct the reconstructed image data sets for possible variabilities in scanner sensitivity.
Image Analysis and Quantification
Reconstructed PET images were visually inspected in three dimensions throughout the body and evaluated by a region-of-interest (ROI) analysis using the dedicated biomedical image quantification software PMOD (Pmod Technologies Ltd, Adliswil Switzerland) [41] . ROIs were drawn manually in all coronal slices comprising the tumor, thus providing volume and average activity concentration of the entire tumor. The average activity concentration in the tumor was then normalized to the injected dose per body weight and expressed as an average standardized uptake value. An alternative approach using the 5% hottest voxels to provide the "maximum SUV" in a tumor was not found to be superior, and experience showed it gave the same results for compound effects on the various tracers.
Tumor Dissection, Histology, and Immunohistochemistry Analysis of Ki67, Proliferating Cell Nuclear Antigen, and Caspase-3
In the [
18 F]FLT experiment, the activity of patupilone was monitored, and histology and immunohistochemistry were performed at several time points of 1, 2, 3, and 6 days posttreatment (n=10 mice per time point). The mice were killed by CO 2 inhalation, and tumor slices were harvested from the largest circumference of the tumor, fixed in 4% phosphate-buffered formaldehyde for 24 h at 4°C, and processed into paraffin as previously described [38] .
IHC was performed on paraffin sections and used the following antibodies for detection of: (1) Microwave-assisted antigen retrieval was carried out for 20 min (caspase-3 and PCNA) or 40 min (Ki67) in 10 mM citrate buffer, pH 6.0. After washing in Tris-buffered saline (TBS), endogenous peroxidase was quenched with 0.5% H 2 O 2 in methanol for 20 min at room temperature. Slides were further incubated with primary antibody: (1) overnight (room temperature) caspase-3 diluted 1/75 or Ki67 diluted 1/100 and (2) 1 h (room temperature) with PCNA diluted 1/2,000. Negative controls were incubated without primary antibody. After washing in TBS, sections were incubated with biotinylated serums followed by avidin-biotin horseradish peroxidase complex (Dako, Glostrup, Denmark). Peroxidase activity was visualized by incubation in a solution of 3.3′-diaminobenzidine tetrahydrochloride (Medite, Nunningen, Switzerland). Sections were counterstained with Mayer's hematoxylin and mounted with Pertex (Medite). Slides were examined with a light microscope (Nikon, Eclipse 600) equipped with a motorized stage, connected to a 3CCD color video camera (Sony, DXC-970 MD). Detection of apoptotic or proliferating nuclei was done automatically using the software "Histolab" (Microvision Instruments). Approximately three to nine frames, covering approximately 10% of the total tumor area, were captured at ×400 magnification in a nonnecrotic and nonhemorrhagic area. The color corresponding to the apoptotic or proliferating nuclei staining and to the non-apoptotic or nonproliferating nuclei one were defined by using the HSI color space, and the percentage of apoptotic or proliferating nuclei was calculated.
Graphics and Statistics
Figures and Table show the mean±SEM, unless stated, and the significance value was set at PG0.05. To test reproducibility of the tracer uptake over more than two studies, a one-way analysis of variance (1W-ANOVA) was performed. To determine the significance of the effect of patupilone treatment, differences between the means of the various parameters measured (TVol, BW, FLT, caspase-3, Ki67, and PCNA) were determined using the raw values, and a 1W-or 2W-ANOVA as appropriate with Tukey post hoc. In addition, the effects at different time points were summarized as the treatment/vehicle-control ratio (T/C), i. 
Results
Tumor Growth
The human tumor s.c. models (H-460, HCT-116, KB-31, DU-145, HT-29, SKOV-3, U87 MG) xenografted into nude athymic mice grew with a doubling time of 2-4 days, and tumors reached a suitable size for imaging 2-3 weeks post cell injection or transplantation (see, for example, O'Reilly et al 2008 [42] ). The exception was the H-596 model which grew much more slowly, only doubling in size every 7- 10 days. The syngeneic rodent tumor models also had doubling times of 2-3 days as has previously been described for B16/BL6 [37] , RIF-1 [43] , and BN472 [34] . The models where human lung H-460-Luc cells were grown intracranially (i.c.) or orthotopically have not previously been described, and their growth as monitored by bioluminescence and the effect of a single dose of patupilone (4 mg/kg i.v.) is shown in Fig. 1 . In both models, BioL was quantifiable ca. 5 days after cell injection and, if the mice were untreated, tumor growth proceeded rapidly, and mice had to be culled 12-14 days post cell injection.
FDG Uptake
We had previously observed that [ 18 F]FDG PET of the human tumor models H-596, KB-31, and HT-29 showed rather low tracer uptake [31] . Here, we have screened additional tumor models for [ 18 (Fig. 2a, b) and BN472 (Fig. 3a) and also in the RIF-1 model (Fig. 3b) , which could be considered orthotopic because it is a fibrosarcoma grown s.c. All the other ten models tested were human tumor xenografts grown in nude athymic mice and showed low [ (Fig. 4a, c) 18 F]FLT uptake was observed for the two syngeneic orthotopic tumors of BN472 in rats (Fig. 3a) and B16/BL6 in mice (Fig. 2a, b) , even though for the latter model, the primary (ear) and main metastases (cervical lymph node) could be clearly visualized. 18 F] FLT were fairly heterogeneous and "spotty," i.e., regions of high and low intensity distributed across the tumor but not necessarily rim-limited (Figs. 4 and 5) .
The tumor model with the strongest [ 18 F]FLT uptake was the human H-460 lung tumor grown i.c. in nude mice, with a very intense tracer accumulation (SUV of 1.3) providing excellent visualization (Fig. 4a) , much better in comparison to the same tumor grown orthotopically in the mouse lung (Fig. 4c) . This tumor was poorly visualized by [ 18 F]FDG also when grown s.c. (Fig. 4b) . It could be detected by [ 18 F] FET but rather poorly by [ 18 F]FCH (Fig. 4) . In general, [ 18 F]FCH provided very poor visualization (Figs. 2, 3, 4 , and 5), with by far the best tracer uptake Table 1 .
detectable in the B16/BL6 model (ear and lymph node). In the other models, tumors were detectable using [ 18 F]FCH in only five out of the eight models investigated (Table 1) . Visualization of tumors with [ 18 F]FET was possible in all seven models and was fairly invariant across the different models (SUV 0.42-0.84), although images were "spotty" and showed low intensity. The highest uptake was again in the B16/BL6 model (Fig. 2a, b) , where both the primary tumor and metastases could be seen.
In summary, of the four tracers compared in these experimental models, [ 18 F]FLT appeared to be the best PET tracer since it provided good visualization in all models with sufficient tracer uptake to expect feasible detection of drug-induced decreases in SUV. ]FLT were used in several different PET studies over 3 years. In order to attain an idea of the inter-experimental variability over this time, the SUVs were compared in rat BN472 tumors and the two human tumor xenografts of H-596 and HCT-116 in athymic nude mice. As Fig. 6 shows, the intra-experimental variability was greater than the inter-experimental variability so that the mean SUVs were fairly invariant over time, and only one (minor) statistically significant difference was detectable, between two of the four [
18 F]FLT experiments using H-596 tumors. (Fig. 7a) . Treatment was well tolerated with no body-weight loss over the whole treatment period, but a dose-dependent effect was apparent in comparison to vehicle: T/C BW =0.99, 0.95, and 0.90 for 1, 3, and 5 mg/kg, respectively (Fig. 7b) . Thus, the highest patupilone dose of 5 mg/kg was selected for the [ 18 F]FLT PET experiment. A preliminary PET experiment with 12 C3H/He mice bearing RIF-1 tumors showed that patupilone caused a significant (P=0.002) decrease in [ A second experiment using 40 mice is summarized in Fig. 8 . This experiment confirmed that patupilone rapidly and highly significantly (PG0.001) decreased the [
18 F]FLT SUV after just 24 h, and this was followed by a slow recovery, but the SUVs remained significantly below those of the vehicle-treated mice. Broadly speaking, these decreases in [ 18 F]FLT uptake were paralleled by decreases in %Ki67, but the effects were smaller and did not reach significance at any single time point, although over the entire treatment period, there was a significant effect (P= 0.03, 2W-ANOVA). Oddly, there was overall a significant increase in PCNA (P=0.02) that was highly significant on day 3 (T/C PCNA =1.5, P=0.002). As expected, there was a significant increase in apoptosis (caspase-3) induced by patupilone which was highly significant overall and most prominent on day 1 (T/C PCNA =2.2, P=0.004). In this experiment, the patupilone treatment was also considered well tolerated because there was no loss in body weight.
Correlations between the various IHC ex vivo parameters and [
18 F]FLT uptake in vivo revealed a weak positive correlation between %Ki67 and [ 18 F]FLT on day 1 (R=0.57, P=0.09, n=10), but none at all over the whole course of the experiment (R=0.1, P=0.5, n=39; Fig. 9a ). In contrast, there was a very strong negative correlation between apoptosis and [ 18 F]FLT on day 1 (R=-0.88, P=0.0009, Fig. 9b ) and over the whole time course (R=-0.72, PG0.0001, Fig. 9c ). For PCNA, 
Discussion
By testing a large panel of 13 different tumor models, it has been possible to confirm our preliminary impression [31] that [ 18 F]FDG PET imaging gives low and rim-limited tracer uptake, especially in human tumor xenografts. Such models tend to have an inadequate blood supply, and indeed tumor blood volume and blood flow has been shown to decrease with increasing tumor size [42] , and consistent with this observation, hypoxia also tends to increase with tumor size [43] . Thus, our data suggest that the static [
18 F]FDG PET images used here may be influenced by blood flow, as are other imaging techniques using i.v. contrast agents such as dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) [37, 44] . Indeed, the syngeneic orthotopic models showed the strongest [
18 F]FDG PET uptake and have previously been demonstrated to be very well vascularized [34, 37, 45] . Although in this study, we did not show if a lower blood flow was associated with hypoxia, a significant correlation has been described in cervical tumors between tumor oxygenation levels and DCE-MRI [46] . Increased hypoxia has been associated with increased glycolysis (via HIF-1 transcriptional up-regulation of numerous glycolytic enzymes) but not always so, and a number of other factors influence glycolysis including the microvasculature [47] . Our experience with many models using both imaging and various histological methods is that human tumor xenografts have a well-perfused rim, a small rim of hypoxia next to this and centrally a small to large necrotic area (tumor-type dependent). Thus, although there may be high glucose uptake and glycolysis at the rim, over the whole tumor, the total [
18 F]FDG uptake is low. In general, low and heterogeneous tracer uptake in experimental tumors represents a complicating factor for proper PET data interpretation. For [ 18 F]FDG PET imaging in rodents, various protocols were suggested to increase tumor uptake [48, 49] . Our own pilot study indicated that tracer uptake times longer than 30 min, and fasting periods up to 6 h do not result in a significant increase in tracer accumulation. We therefore refrained from fasting and focused on a strict standardization of injection and acquisition protocols to keep inter-individual variability at a minimum. Additionally, the quantitative assessment of the heterogeneity of tracer uptake within a tumor is considered to be another major challenge in small animal PET imaging. To detect the effect of a drug on the vital portion of an experimental tumor, the determination of a "maximum SUV" (only including the hottest voxels of the tumor ROI) might be more meaningful compared to a ROI comprising the entire tumor volume. However, when we directly compared mean SUV with maximum SUV, we found no difference in the outcome of the effect of a compound. Thus, we came to the conclusion that such an analysis might be biased by other factors such as partial volume loss, and we opted for the average SUV of the whole tumor volume as the most appropriate indicator of tracer uptake. Clearly, small animal PET imaging is characterized by limitations such as the lack of fully quantitative reconstruction software (e.g., correcting for partial volume loss) or the inaccurate ROI delineation in the absence of any anatomical information. Nevertheless, the [ 18 F]FLT PET appeared to provide the best imaging parameters across all models, and thus we used this tracer as a non-invasive early-response biomarker to investigate the effect of the novel microtubule stabilizer patupilone. Patupilone is a cytotoxic which rapidly inhibits tumor growth in vivo and causes apoptosis [34, 42] , and thus, [ 18 F]FLT PET seemed to be suitable for this compound class. We selected the RIF-1 mouse tumor model because of high sensitivity and very good tolerability of the mice to patupilone and because ablation for IHC was easier than in the H-460-Luc model which, although showing a high [ 18 F] FLT uptake, were very small and difficult to locate. The results in the RIF-1 tumor showed that patupilone caused the expected decrease in [
18 F]FLT already within 24 h, but the correlation with the proliferation markers Ki67 or PCNA was relatively weak compared with those in the literature reviewed by Apisarnthanarax [50] . Actually, both of these markers are expressed throughout the cell cycle, rather than just in S-phase, and Ki67 can show higher levels in mitosis [51] , and PCNA may even be expressed by noncycling cells and has a long half-life [52] . Thus, these markers may not be ideal for detecting the effect of a drug which causes cells to accumulate in G2M prior to apoptosis [32] . In contrast, uptake of [ F]FLT by cells depends predominantly on the enzyme thymidine kinase-1, which is only expressed in Sphase [53] . Thus, the best ex vivo marker, or correlate, for [ 18 F]FLT is really TK-1 [13, [50] [51] [52] [53] , but this is not routinely used in the clinic. However, caspase-3 as a marker for apoptosis is used in the clinic, and the data presented here showed a very strong correlation between [ 18 F]FLT and caspase-3.
Conclusions
Our analysis of several different tumor models and four different fluorinated tracers led us to conclude that, aside from [
18 F]FDG, [ 18 F]FLT was likely to be the best all-round candidate for routine application as an early-response marker for anti-cancer compounds. [ 18 F]FET also showed some potential, while on the other hand, [ 18 F]FCH proved not to be a good generic tracer for animal tumors. As an example, [ 18 F]FLT was tested in a murine fibrosarcoma using the novel cytotoxic patupilone, and the results showed that this tracer was an excellent marker for apoptosis induced by patupilone, suggesting that this non-invasive technique could usefully be applied as an early tumor-response marker for the clinical development of the compound.
